H.C. Wainwright notes that the FDA sent a letter to the Federal Register withdrawing the notice regarding the Advisory Committee for deramiocel, which Capricor had just recently announced was being held on July 30 ahead of the August 31 PDUFA date, and that “volatility in the shares abound with trying to read the tea leaves.” The firm’s positive thesis on deramiocel being approved remains unchanged and it believes the impact on the shares from the latest piece of news is an “overreaction.” The firm, which urges investors “calm down,” contends that today’s pullback represents a buying opportunity and it keeps a Buy rating and $77 price target on Capricor Therapeutics (CAPR) shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics put volume heavy and directionally bearish
- Capricor weakness attributed to FDA letter on advisory meeting
- Capricor Therapeutics’ Strategic Advances and Market Positioning Boost Buy Rating for Deramiocel in DMD Treatment
- H.C. Wainwright says Capricor path to approval ‘sharpens’ with inspection done
- Promising Regulatory Progress and Upcoming Milestones Support Buy Rating for Capricor Therapeutics